Levothyroxine liquid formulations
The present invention is directed to a pharmaceutical product which includes a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes tromethamine, sodium iodide, and water and has a pH of about 9.0 to about 11.5. The liquid formulation according to the invention is stable and ready-to-use.
1. A pharmaceutical product comprising a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof, a stabilizing agent comprising an amine selected from one or more of tromethamine, bis(2-hydroxyethyl)-imino-tris(hydroxymethyl)methane, monoethanolamine, diethanolamine, triethanolamine, 2-amino-2-methyl-1,3-propanediol, 2-dimethylamino-2-methyl-1-propanediol, 2-amino-2-ethylpropanol, 2-amino-1-butanol, and 2-amino-2-methyl-1-propanol, and water, wherein the formulation retains at least 95% of the initial concentration of levothyroxine or pharmaceutically acceptable salt thereof after storage for two months at 40° C. and retains at least 95% of the initial concentration of levothyroxine or pharmaceutically acceptable salt thereof after storage for at least 12 months at room temperature.
2. The pharmaceutical product of claim 1 , wherein the levothyroxine or a pharmaceutically acceptable salt thereof is levothyroxine sodium.
3. The pharmaceutical product of claim 2 , wherein levothyroxine sodium is present at a concentration of from about 5 mcg/mL to about 500 mcg/mL.
4. The pharmaceutical product of claim 1 , wherein the amine is tromethamine which is present at a concentration of about 1 mg/mL to about 50 mg/mL.
5. The pharmaceutical product of claim 1 , wherein the stabilizing agent further comprises a salt of iodine.
6. The pharmaceutical product of claim 5 , wherein the salt of iodine is sodium iodide or potassium iodide.
7. The pharmaceutical product of claim 6 , wherein the salt of iodine is sodium iodide which is present at a concentration of about 10 mcg/mL to about 500 mcg/mL.
8. The pharmaceutical product of claim 1 , wherein the formulation has a pH of from about 9.0 to about 11.5.
9. The pharmaceutical product of claim 8 , wherein the formulation has a pH of from about 9.8 to about 10.8.
10. The pharmaceutical product of claim 1 , wherein the formulation contains not more than 2.0% liothyronine (T3).
11. The pharmaceutical product of claim 1 , wherein the formulation contains not more than 5.0% total impurities.
12. The pharmaceutical product of claim 1 , wherein the formulation retains at least about 90% of the initial concentration of levothyroxine or pharmaceutically acceptable salt thereof after storage for at least 18 months at room temperature.
13. The pharmaceutical product of claim 1 , wherein the formulation does not contain a buffer.
14. The pharmaceutical product of claim 1 , wherein the formulation is contained within a clear glass container.
15. The pharmaceutical product of claim 14 , wherein the clear glass container is a flint colored, molded vial, ampoule, cartridge, or syringe.
16. The pharmaceutical product of claim 14 , wherein the clear glass container is not treated with ammonium sulfate.